Form 4 for ELVN Enliven Therapeutics, Inc.
Accepted 2025-09-25 00:00:00 ET · period of report 2025-09-23 · accession 0001967168-25-000005 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2025-09-25 | 2025-09-23 | ELVN | Kintz Samuel | Pres AND CEO, Dir | S - Sale | $20.03 | -2,800 | 919.1K | -0.3% | -$56.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-09-23 | S | D | 2,800 | $20.03 | 919,092 | I See footnote | — | — | (F2) The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee. |